Clinical Practice Guideline Developed for Treatment of H. Pylori Infection
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 9, 2024 -- In a clinical practice guideline issued by the American College of Gastroenterology and published in the September issue of the American Journal of Gastroenterology, recommendations are presented for the treatment of patients with Helicobacter pylori (H. pylori) infection.
William D. Chey, M.D., from Michigan Medicine in Ann Arbor, and colleagues developed a clinical practice guideline to inform evidence-based management of patients with H. pylori infection in North America. Eleven population, intervention, comparison, and outcome questions were analyzed and recommendations were generated. Expert consensus was used to create six key concepts in cases of insufficient evidence.
According to the authors, when antibiotic susceptibility is unknown, bismuth quadruple therapy (BQT) for 14 days is the preferred regimen for treatment-naive patients with H. pylori infection. For patients without penicillin allergy, rifabutin triple therapy or potassium-competitive acid blocker dual therapy for 14 days is a suitable empiric alternative. Optimized BQT for 14 days is preferred in treatment-experienced patients with persistent H. pylori infection who have not been previously treated with optimized BQT and for whom antibiotic susceptibility is unknown. Fourteen days of rifabutin triple therapy is a suitable empiric alternative in patients previously treated with optimized BQT. Only if antibiotic susceptibility is confirmed should salvage regimens containing clarithromycin or levofloxacin be used.
"In preparing this clinical practice guideline, we identified key knowledge gaps in the management of patients diagnosed with H. pylori infection or at risk of harboring H. pylori infection in North America, specifically, and these should be acknowledged as research priorities," the authors write. "One such research priority is identifying which individuals residing in North America are most likely to benefit from opportunistic H. pylori testing."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Odds of IBS, Functional Dyspepsia Increased After Acute Gastroenteritis Episode
WEDNESDAY, July 17, 2024 -- A considerable proportion of individuals experiencing acute gastroenteritis develop postinfection irritable bowel syndrome (PI-IBS) and postinfection...
Gastroesophageal Reflux Disease Increases Risk for Atrial Fibrillation
TUESDAY, July 2, 2024 -- Gastroesophageal reflux disease (GERD) is associated with an increased incidence of atrial fibrillation, according to a study published online June 2...
Use of Acid-Suppression Therapy Linked to Migraine, Severe Headache
FRIDAY, April 26, 2024 -- Use of acid-suppression therapy is associated with higher odds of migraine or severe headache, according to a study published online April 24 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.